Aktuelle Koronarstenttechnologie

Schlüsselwörter

Koronarstenosen - Stents - medikamentenfreisetzende Stents - bioresorbierbare Stents

Keywords

coronary stenoses - stents - drug-eluting stents - DES - bioresorbable vascular scaffold - BVS

• Literatur

• 1 Bayer HealthCare. Presse-Information, Neue Studie mit Xarelto® (Rivaroxaban) von Bayer bei Patienten mit nicht-valvulärem Vorhofflimmern, die sich einer perkutanen Koronarintervention mit Stenteinsatz unterziehen. Berlin: 08.03.2013
• 2 Bourantas CV, Zhang Y, Farooq V et al. Bioresorbable scaffolds: Current evidence and ongoing clinical trials. Current Cardiolo Rep 2012; 14: 626-634
• 3 Gogas BD, Bourantas C, Garcia-Garcia HM et al. The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the Xience V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and Spirit II trials. Eurointervention 2013; 9: 709-720
• 4 Kaiser C, Galatius S, Erne P. BASKET–PROVE Study Group et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363: 2310-2319
• 5 Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-e122
• 6 Onuma Y, Dudek D, Thuesen L et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013; 6: 999-1009
• 7 Sabate M, Cequier A, Iñiguez A et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380: 1482-90
• 8 Sipahi I, Akay MH, Dagdelen S et al. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting Era. JAMA Intern Med 2013; Dec 2 DOI: 10.1001/jamainternmed.2013.12844. [Epub ahead of print]
• 9 Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-2011
• 10 Stefanini GG, Holes DR. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368: 254-65